Compugen Ltd.

NasdaqCM:CGEN Lagerbericht

Marktkapitalisierung: US$153.1m

Compugen Management

Management Kriterienprüfungen 3/4

Compugen's CEO is Anat Cohen-Dayag, appointed in Jun 2009, has a tenure of 15.42 years. total yearly compensation is $1.46M, comprised of 32.7% salary and 67.3% bonuses, including company stock and options. directly owns 0.063% of the company’s shares, worth $95.97K. The average tenure of the management team and the board of directors is 5 years and 7.4 years respectively.

Wichtige Informationen

Anat Cohen-Dayag

Geschäftsführender

US$1.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts32.7%
Amtszeit als Geschäftsführer15.4yrs
Eigentum des Geschäftsführers0.06%
Durchschnittliche Amtszeit des Managements5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.4yrs

Jüngste Management Updates

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Compugen Q3 Earnings Preview

Nov 04

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Anat Cohen-Dayag im Vergleich zu den Einnahmen von Compugen verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$1mUS$479k

-US$19m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$479k

-US$34m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$1mUS$498k

-US$34m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$453k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$941kUS$395k

-US$27m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$854kUS$391k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$740kUS$392k

-US$37m

Vergütung im Vergleich zum Markt: Anat's total compensation ($USD1.46M) is about average for companies of similar size in the US market ($USD1.48M).

Entschädigung vs. Einkommen: Anat's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Anat Cohen-Dayag (57 yo)

15.4yrs

Amtszeit

US$1,464,448

Vergütung

Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Anat Cohen-Dayag
CEO, President & Director15.4yrsUS$1.46m0.063%
$ 96.0k
Eran Ophir
Chief Scientific Officer4.7yrsUS$540.64kkeine Daten
Zurit Levine
Senior Vice President of Technology Innovation6.8yrsUS$532.26kkeine Daten
Pierre Ferre
Vice President of Preclinical Development3.6yrsUS$570.40kkeine Daten
David Silberman
Chief Financial Officerless than a yearkeine Datenkeine Daten
Yvonne Naughton
Head of Investor Relations & Corporate Communicationsno datakeine Datenkeine Daten
Eran Dor
General Counsel & Corporate Secretary5.8yrskeine Datenkeine Daten
Dorit Amitay
Vice President of Human Resources17.8yrskeine Datenkeine Daten
Yaron Turpaz
Senior VP & Senior Advisor of Data and Informatics Solutions5yrskeine Datenkeine Daten
Rivka Schwartz
Vice President Research and Discoveryno datakeine Datenkeine Daten
Michelle Mahler
Chief Medical Officerless than a yearkeine Datenkeine Daten

5.0yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrenes Management: CGEN's management team is seasoned and experienced (5 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Anat Cohen-Dayag
CEO, President & Director10.8yrsUS$1.46m0.063%
$ 96.0k
Nils Lonberg
Member of Scientific Advisory Board4.2yrskeine Datenkeine Daten
Sanford Zweifach
Independent Director6.4yrskeine Datenkeine Daten
Howard Soule
Member of Scientific Advisory Board11.3yrskeine Datenkeine Daten
Gilead Halevy
Independent Director6.4yrskeine Datenkeine Daten
Paul Sekhri
Independent Chairman of the Board7.1yrskeine Datenkeine Daten
Kinneret Livnat-Savitzky
Independent Director6.4yrskeine Datenkeine Daten
Andrew Pardoll
Chairman of Scientific Advisory Board10.8yrskeine Datenkeine Daten
Antoni Ribas
Member of Scientific Advisory Board11.3yrskeine Datenkeine Daten
Eran Perry
Independent Director5.3yrskeine Datenkeine Daten
Iain McInnes
Member of Scientific Advisory Board11.3yrskeine Datenkeine Daten
Miriam Merad
Member of Scientific Advisory Board7.7yrskeine Datenkeine Daten

7.4yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: CGEN's board of directors are considered experienced (7.4 years average tenure).